EE+ POEM Archive
Omalizumab = modest benefit, high cost for children with allergic asthma
There's more to see -- the rest of this topic is available only to subscribers.
Citation
Barry, Henry, et al., editors. "Omalizumab = Modest Benefit, High Cost for Children With Allergic Asthma." EE+ POEM Archive, John Wiley & Sons, 2019. Evidence Central, evidence.unboundmedicine.com/evidence/view/infoPOEMs/427266/all/Omalizumab_=_modest_benefit__high_cost_for_children_with_allergic_asthma.
Omalizumab = modest benefit, high cost for children with allergic asthma. In: Barry HH, Ebell MHM, Shaughnessy AFA, et al, eds. EE+ POEM Archive. John Wiley & Sons; 2019. https://evidence.unboundmedicine.com/evidence/view/infoPOEMs/427266/all/Omalizumab_=_modest_benefit__high_cost_for_children_with_allergic_asthma. Accessed October 13, 2024.
Omalizumab = modest benefit, high cost for children with allergic asthma. (2019). In Barry, H., Ebell, M. H., Shaughnessy, A. F., & Slawson, D. C. (Eds.), EE+ POEM Archive. John Wiley & Sons. https://evidence.unboundmedicine.com/evidence/view/infoPOEMs/427266/all/Omalizumab_=_modest_benefit__high_cost_for_children_with_allergic_asthma
Omalizumab = Modest Benefit, High Cost for Children With Allergic Asthma [Internet]. In: Barry HH, Ebell MHM, Shaughnessy AFA, Slawson DCD, editors. EE+ POEM Archive. John Wiley & Sons; 2019. [cited 2024 October 13]. Available from: https://evidence.unboundmedicine.com/evidence/view/infoPOEMs/427266/all/Omalizumab_=_modest_benefit__high_cost_for_children_with_allergic_asthma.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Omalizumab = modest benefit, high cost for children with allergic asthma
ID - 427266
ED - Barry,Henry,
ED - Ebell,Mark H,
ED - Shaughnessy,Allen F,
ED - Slawson,David C,
BT - EE+ POEM Archive
UR - https://evidence.unboundmedicine.com/evidence/view/infoPOEMs/427266/all/Omalizumab_=_modest_benefit__high_cost_for_children_with_allergic_asthma
PB - John Wiley & Sons
DB - Evidence Central
DP - Unbound Medicine
ER -
